secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2024-10-10T23:59:59+00:00
Accession:  0001493152-24-040752
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Israeli Ministry of Health approves Elite's generic Adderall; first shipment months away
--------------------------------------------------------------------------------

- Israeli Ministry of Health approved Elite's generic Adderall (mixed amphetamine salts) in 10mg, 20mg, 30mg tablets on Oct 7, 2024.
- Elite will supply to exclusive distributor Dexcel Pharma for the Israeli market; Dexcel handles sales/marketing at its expense.
- Product jointly owned by Elite and Mikah Pharma; first shipment depends on licensee orders, DEA quotas, and manufacturing.
- Under license agreement, Dexcel pays transfer price and shares profits under certain conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315224040752/0001493152-24-040752-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315224040752/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-040752

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer